208 related articles for article (PubMed ID: 21706358)
1. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.
Norden AD; Bartolomeo J; Tanaka S; Drappatz J; Ciampa AS; Doherty LM; Lafrankie DC; Ruland S; Quant EC; Beroukhim R; Wen PY
J Neurooncol; 2012 Jan; 106(1):121-5. PubMed ID: 21706358
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents.
Perry JR
Curr Opin Neurol; 2010 Dec; 23(6):592-6. PubMed ID: 20881488
[TBL] [Abstract][Full Text] [Related]
3. Safety of anticoagulation use and bevacizumab in patients with glioma.
Nghiemphu PL; Green RM; Pope WB; Lai A; Cloughesy TF
Neuro Oncol; 2008 Jun; 10(3):355-60. PubMed ID: 18436627
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation.
Zwicker JI; Karp Leaf R; Carrier M
J Thromb Haemost; 2016 Sep; 14(9):1736-40. PubMed ID: 27306689
[TBL] [Abstract][Full Text] [Related]
6. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.
Mantia C; Uhlmann EJ; Puligandla M; Weber GM; Neuberg D; Zwicker JI
Blood; 2017 Jun; 129(25):3379-3385. PubMed ID: 28468796
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
Nagane M; Nishikawa R; Narita Y; Kobayashi H; Takano S; Shinoura N; Aoki T; Sugiyama K; Kuratsu J; Muragaki Y; Sawamura Y; Matsutani M
Jpn J Clin Oncol; 2012 Oct; 42(10):887-95. PubMed ID: 22844129
[TBL] [Abstract][Full Text] [Related]
8. Safety of bevacizumab in patients with malignant gliomas: a systematic review.
Simonetti G; Trevisan E; Silvani A; Gaviani P; Botturi A; Lamperti E; Beecher D; Bertero L; Bosa C; Salmaggi A
Neurol Sci; 2014 Jan; 35(1):83-9. PubMed ID: 24281944
[TBL] [Abstract][Full Text] [Related]
9. D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma.
Misch M; Czabanka M; Dengler J; Stoffels M; Auf G; Vajkoczy P; Stockhammer F
Anticancer Res; 2013 May; 33(5):2093-8. PubMed ID: 23645760
[TBL] [Abstract][Full Text] [Related]
10. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
Cabrera AR; Cuneo KC; Desjardins A; Sampson JH; McSherry F; Herndon JE; Peters KB; Allen K; Hoang JK; Chang Z; Craciunescu O; Vredenburgh JJ; Friedman HS; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):873-9. PubMed ID: 23725997
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Fangusaro J; Gururangan S; Poussaint TY; McLendon RE; Onar-Thomas A; Warren KE; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Kun LE; Fouladi M
Cancer; 2013 Dec; 119(23):4180-7. PubMed ID: 24104527
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
14. Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta-analysis.
Porfidia A; Giordano M; Sturiale CL; D'Arrigo S; Donadini MP; Olivi A; Ageno W; Pola R
Brain Behav; 2020 Jun; 10(6):e01638. PubMed ID: 32314875
[TBL] [Abstract][Full Text] [Related]
15. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.
Di Stefano AL; Labussiere M; Lombardi G; Eoli M; Bianchessi D; Pasqualetti F; Farina P; Cuzzubbo S; Gallego-Perez-Larraya J; Boisselier B; Ducray F; Cheneau C; Moglia A; Finocchiaro G; Marie Y; Rahimian A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M
J Neurooncol; 2015 Feb; 121(3):499-504. PubMed ID: 25488073
[TBL] [Abstract][Full Text] [Related]
16. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
[TBL] [Abstract][Full Text] [Related]
17. Safety of Anticoagulant Therapy Including Direct Oral Anticoagulants in Patients With Acute Spontaneous Intracerebral Hemorrhage.
Sakamoto Y; Nito C; Nishiyama Y; Suda S; Matsumoto N; Aoki J; Shimoyama T; Kanamaru T; Suzuki K; Nishimura T; Mishina M; Kimura K
Circ J; 2019 Jan; 83(2):441-446. PubMed ID: 30587698
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.
Sahebjam S; Garoufalis E; Guiot MC; Muanza T; Del Maestro R; Petrecca K; Sharma R; Kavan P
Can J Neurol Sci; 2013 Mar; 40(2):241-6. PubMed ID: 23419575
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
[TBL] [Abstract][Full Text] [Related]
20. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.
Khasraw M; Holodny A; Goldlust SA; DeAngelis LM
Ann Oncol; 2012 Feb; 23(2):458-63. PubMed ID: 21543627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
